BNOX vs. MEIP, HCWB, CARA, TXMD, KALA, JAN, IBIO, ALTS, APM, and PMCB
Should you be buying Bionomics stock or one of its competitors? The main competitors of Bionomics include MEI Pharma (MEIP), HCW Biologics (HCWB), Cara Therapeutics (CARA), TherapeuticsMD (TXMD), KALA BIO (KALA), JanOne (JAN), iBio (IBIO), Janone (ALTS), Aptorum Group (APM), and PharmaCyte Biotech (PMCB). These companies are all part of the "pharmaceutical products" industry.
Bionomics (NASDAQ:BNOX) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends, risk and community ranking.
15.9% of Bionomics shares are held by institutional investors. Comparatively, 52.4% of MEI Pharma shares are held by institutional investors. 1.5% of Bionomics shares are held by company insiders. Comparatively, 3.9% of MEI Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Bionomics has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
MEI Pharma received 367 more outperform votes than Bionomics when rated by MarketBeat users. However, 75.00% of users gave Bionomics an outperform vote while only 61.11% of users gave MEI Pharma an outperform vote.
In the previous week, MEI Pharma had 10 more articles in the media than Bionomics. MarketBeat recorded 12 mentions for MEI Pharma and 2 mentions for Bionomics. Bionomics' average media sentiment score of 0.38 beat MEI Pharma's score of -0.15 indicating that Bionomics is being referred to more favorably in the media.
MEI Pharma's return on equity of 48.32% beat Bionomics' return on equity.
Bionomics presently has a consensus target price of $9.00, suggesting a potential upside of 1,223.72%. MEI Pharma has a consensus target price of $7.00, suggesting a potential upside of 96.63%. Given Bionomics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Bionomics is more favorable than MEI Pharma.
Bionomics has higher earnings, but lower revenue than MEI Pharma.
Summary
MEI Pharma beats Bionomics on 8 of the 15 factors compared between the two stocks.
Get Bionomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNOX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bionomics Competitors List
Related Companies and Tools
